IFM Investors Pty Ltd Buys Shares of 24,734 Natera, Inc. $NTRA

Key Points

• IFM Investors Pty Ltd has invested approximately $3.50 million in Natera, Inc., acquiring 24,734 shares of the company.
• Natera reported a revenue increase of 32.2% year-over-year, with total revenue reaching $546.60 million, although it missed EPS estimates by $0.14.
• Major institutional investors, including Intech Investment Management LLC and UBS AM, have significantly increased their stakes in Natera during the first quarter.

IFM Investors Pty Ltd purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 24,734 shares of the medical research company's stock, valued at approximately $3,498,000.

Other hedge funds also recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in shares of Natera during the first quarter valued at approximately $29,000. Rakuten Securities Inc. raised its holdings in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after buying an additional 119 shares during the last quarter. ORG Partners LLC bought a new stake in Natera during the first quarter worth approximately $32,000. TCTC Holdings LLC lifted its position in Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after purchasing an additional 106 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In other Natera news, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the transaction, the director owned 8,118 shares of the company's stock, valued at $1,358,628.48. The trade was a 34.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 6,092 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $851,722.52. Following the completion of the sale, the chief executive officer directly owned 169,400 shares of the company's stock, valued at $23,683,814. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,423 shares of company stock valued at $8,459,656 in the last ninety days. Company insiders own 5.63% of the company's stock.

Natera Trading Down 3.0%

Shares of NTRA traded down $5.30 during midday trading on Friday, hitting $168.51. The stock had a trading volume of 853,091 shares, compared to its average volume of 945,987. The business has a 50-day simple moving average of $155.18 and a two-hundred day simple moving average of $154.12. The firm has a market cap of $23.13 billion, a P/E ratio of -88.23 and a beta of 1.68. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. During the same quarter last year, the company posted ($0.30) EPS. The firm's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Piper Sandler reissued an "overweight" rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Barclays reaffirmed an "overweight" rating and set a $210.00 target price (up from $190.00) on shares of Natera in a report on Friday, August 8th. Cowen reissued a "buy" rating on shares of Natera in a report on Friday, August 8th. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Finally, Evercore ISI raised shares of Natera to a "strong-buy" rating and set a $170.00 target price for the company in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.